$SER News

Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Completes Enrollment And Dosing In Cohort 1 Of Ongoing Phase 1b Registrational Clinical Trial Evaluating SER-252 In Patients With Advanced Parkinson’s Disease

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease

Serina Therapeutics Completes Sentinel Dosing In Group 1 Of Its Phase 1b Study Of SER-252 To Treat Parkinson's Disease

BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8

Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program

Gannet BioChem To Support Development Activities For SER-252, Serina Therapeutics' Investigational Therapy For Advanced Parkinson's Disease

Serina Therapeutics Files Prospectus For Offering 16.45M Common Shares On Behalf Of Selling Stockholders

Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027

Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate

Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit

Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

NYSE Accepts Serina Therapeutics Plan To Regain Compliance

NYSE Accepts Serina Therapeutics Plan To Regain Compliance

Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate

Serina Therapeutics to Present at the 38th Annual Roth Conference